FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

obligations may Instruction 1(b).	continue. See	Fil	led pursuant to Section 16(a) of the Securities Exchange Act of 1934		hours per response:		
			or Section 30(h) of the Investment Company Act of 1940				
1. Name and Addre	ss of Reporting Person	n*	2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]		tionship of Real all applicable	eporting Persone)	n(s) to Issuer
CHESS ROD	EKI			X	Director		10% Owner
					Officer (giv	e title	Other (specify
(Last) C/O NEKTAR T	(First) THERAPEUTICS	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 09/22/2020		below)		below)
455 MISSION E	BAY BOULEVARI	O SOUTH					
(Street) SAN FRANCISCO	CA	94158	4. If Amendment, Date of Original Filed (Month/Day/Year) 09/24/2020	6. Indiv Line) X	Form filed	/Group Filing (i by One Report by More than C	ŭ
(City)	(State)	(Zip)	-		Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	v	Amount	(A) or Price		Transaction(s) (Instr. 3 and 4)		(IIISU. 4)		
Common Stock ⁽¹⁾	09/22/2020	(2)	A		9,100	Α	\$0.00	286,073	D			

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$19.9	09/22/2020		A		18,200		(3)	09/21/2028	Common Stock	18,200	\$0.00	18,200	D	

Explanation of Responses:

- 1. This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.
- 2. This restricted stock unit award vests in full, one year following September 22, 2020.
- 3. This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020.

Remarks:

This amendment is being filed solely to correct the exercise price previously reported for this option grant. All other information in the original Form 4 remains the same.

Mark A. Wilson, Attorney-in-<u>Fact</u>

** Signature of Reporting Person Date

09/25/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.